Company: RGNT
Filing Date: 2025-09-30
Form Type: F-1/A
Source: 0001213900-25-093302
Chunk: 288

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-09-30
Form: F-1/A
Chunk 288
---
 (“Merger Sub”), Aspire Acquisition LLC, OceanTech’s sponsor (the “Sponsor”), and the Company
executed a definitive Agreement and Plan of Merger (the “Merger Agreement”) pursuant to which, among other things, Merger
Sub will merge with and into the Company (the “Merger”), with the Company surviving the Merger as a wholly owned subsidiary
of OceanTech. In May 2024, due to OceanTech not meeting certain Nasdaq compliance requirements, the Company and OceanTech couldn’t
proceed with the Merger and as a result the Merger Agreement was cancelled.

| c. | Forward share split |

On March 20, 2025, the Company effected
a two and a half-for-one (2.5-for-1) forward share split of its ordinary shares, no par value (the “Ordinary Shares”), and
all classes of its preferred shares (the “Split”). As a result of the Split, each one (1) Ordinary Share or preferred share,
as applicable, issued and outstanding at the time of the Split, was split into two and a half (2.5) Ordinary Shares or preferred shares,
as applicable. All outstanding securities entitling their holders the right to purchase Ordinary Shares, including, warrants and share
options, were adjusted as a result of the Split, as required by the terms of those securities. All share amounts, share prices, and exercise
prices have been adjusted retroactively within these financial statements to reflect the Split. On March 20, 2025, at the general meeting
of the Company’s shareholders, the shareholders of the Company approved an increase of the authorized share capital of the Company and
cancellation of the par value of the Ordinary Shares and the Company’s preferred shares .

| d. | Going concern and management plans |

The accompanying condensed unaudited
financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and satisfaction of liabilities
in the normal course of business. Since its inception, the Company has devoted substantially all of its efforts to research and development,
clinical trials, and raising capital. The Company is still in its development and clinical stage and has not yet generated revenues.
The extent of the Company’s future operating losses and the timing of becoming profitable are uncertain. The Company has incurred loss
of $3,228 for the six months period ended June 30, 2025. As of June 30, 2025, the Company’s